Marcio Kiuchi

Dr. Marcio Kiuchi

Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Royal Perth Hospital, University of Western Australia, Perth, Australia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Hypertension
Verified
Journal Article
Closed access
GSGianni Sesa-Ashton
Gianni Sesa-Ashton
JNJanis Nolde
Janis Nolde
IMIda Muente
Ida Muente
RCRevathy Carnagarin
Revathy Carnagarin
RLRebecca Lee
Rebecca Lee
MSMarkus P SCHLAICH
Markus P SCHLAICH
Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by −12.1±21.6 (from 145.2 to 133.1) mm Hg ( P <0.0001) and diastolic BP by −8.8±12.8 (from 81.2 to 72.7) mm Hg ( P <0.0001). Mean heart rate remained unchanged. At long-term FU, participants were on one less antihypertensive medication compared with baseline ( P =0.0052). Renal function assessed by estimated glomerular filtration rate fell within the expected age-associated rate of decline from 71.1 to 61.2 mL/min per 1.73 m 2 . Time above target was reduced significantly from 75.0±25.9% at baseline to 47.3±30.3% at long-term FU ( P <0.0001). Conclusions: RDN results in a significant and robust reduction in both office and ambulatory systolic and diastolic BP at ≈9-year FU after catheter-based RDN on less medication and without evidence of adverse consequences on renal function.

1 June 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
LGLeslie Marisol Lugo Gavida
Leslie Marisol Lugo Gavida
DBDylan Burger
Dylan Burger
VMVance B. Matthews
Vance B. Matthews
JNJanis Nolde
Janis Nolde
MKMarcio Kiuchi
Marcio Kiuchi
MSMarkus P SCHLAICH
Markus P SCHLAICH
Microparticles are small cell vesicles that are derived from the cell membrane in response to different biological processes. There is growing evidence supporting the association between microparticles and cardiovascular disease, as their pathophysiology commonly includes endothelial damage and chronic inflammation which also promote a prothrombotic state. The direct causal link between the release of the different subtypes of microparticles and their implications on physiological and pathological conditions is still not completely elucidated. However, evidence suggests microparticles released from platelets, leukocytes, and endothelium may help to evaluate vascular health as they have a relevant role in inflammation, endothelial function, and thrombosis. This review aims to provide a short overview of the biogenesis, characteristics, and detection methodology of microparticles with a special focus on their possible implication in cardiovascular settings.

Verified
Journal Article
Open access
PDF file
RCRevathy Carnagarin
Revathy Carnagarin
KTKearney Tan
Kearney Tan
LALeon Adams
Leon Adams
VMVance Matthews
Vance Matthews
MKMarcio Kiuchi
Marcio Kiuchi
MSMarkus P SCHLAICH
Markus P SCHLAICH
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease affecting a quarter of the global population and is often associated with adverse health outcomes. The increasing prevalence of MAFLD occurs in parallel to that of metabolic syndrome (MetS), which in fact plays a major role in driving the perturbations of cardiometabolic homeostasis. However, the mechanisms underpinning the pathogenesis of MAFLD are incompletely understood. Compelling evidence from animal and human studies suggest that heightened activation of the sympathetic nervous system is a key contributor to the development of MAFLD. Indeed, common treatment strategies for metabolic diseases such as diet and exercise to induce weight loss have been shown to exert their beneficial effects at least in part through the associated sympathetic inhibition. Furthermore, pharmacological and device-based approaches to reduce sympathetic activation have been demonstrated to improve the metabolic alterations frequently present in patients with obesity, MetSand diabetes. Currently available evidence, while still limited, suggests that sympathetic activation is of specific relevance in the pathogenesis of MAFLD and consequentially may offer an attractive therapeutic target to attenuate the adverse outcomes associated with MAFLD.

30 June 2018 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
MKMarcio Kiuchi
Marcio Kiuchi
Márcio Galindo Kiuchi. Kidney Res Clin Pract 2018;37:103-5. https://doi.org/10.23876/j.krcp.2018.37.2.103

20 December 2017 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
MKMarcio Kiuchi
Marcio Kiuchi
SCShaojie Chen
Shaojie Chen
NHNeil Alexander Hoye
Neil Alexander Hoye
HPHelmut Pürerfellner
Helmut Pürerfellner

1 August 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
Shaojie ChenShaojie Chen
Shaojie Chen
SNSanjiv M. Narayan
Sanjiv M. Narayan
SBSerge Boveda
Serge Boveda
KNKars Neven
Kars Neven
MRMartin H. Ruwald
Martin H. Ruwald
HPHelmut Purerfellner
Helmut Purerfellner
Pulsed field ablation (PFA) has been developed as a largely nonthermal ablation technology with a unique biophysical profile to treat atrial fibrillation. Existing evidence has shown that PFA offers a safe and efficient atrial fibrillation ablation procedure. Among different PFA technologies, the pentaspline FARAPULSE system has been the most extensively used and investigated; however, notable variability exists in workflow, fluoroscopy time, and lesion durability. While innovations such as 3-dimensional electroanatomic mapping systems and intracardiac echocardiography can enhance procedural precision in catheter ablation, fluoroscopy remains the primary imaging modality for guiding pentaspline PFA in many electrophysiology labs worldwide. This is particularly true in centers where limitations in cost, infrastructure, or training may preclude the routine use of advanced imaging technologies. This article summarizes general practical considerations and presents a primarily fluoroscopy-based, refined workflow developed by a group of experts. The goal is to provide a procedural foundation and practical guide for using the pentaspline FARAPULSE PFA system in atrial fibrillation ablation procedures. Developing a fluoroscopy-based practical guide would: (1) Democratize access to PFA technology, enabling safe and effective implementation across a broader range of clinical settings, including those without intracardiac echocardiography or 3-dimensional mapping support; (2) Reduce procedural heterogeneity by offering reproducible best practices; (3) Facilitate meaningful intercenter comparisons of procedural efficacy and safety, aiding in the identification of optimal approaches and improving the quality of clinical data for ongoing research, registries, and real-world performance monitoring of PFA technologies; and (4) Ultimately improve patient outcomes through standardized, accessible, and evidence-based practices.